Earnings per share for the last twelve months: Dyne Therapeutics Inc (DYN)

Public company logo of Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics, Inc. (DYN) leverages outsourced manufacturing and testing to optimize global access to its drugs. The fundamental EPS TTM metric clearly confirms the impact of these processes, where the value of -3.66 serves as the current indicator. Growth is based on the FORCE platform and FDA approval, while high patient loyalty within the dystrophy treatment ecosystem ensures a stable expansion of the user base.

DYN Dyne Therapeutics, Inc. Net earnings per one share for the last twelve months (07/04/2022 - 11/16/2026)

Analytical breakdowns and data insights for company Dyne Pharma (DYN)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Comprehensive company analysis:Dyne Corp - DYN
Mass-produced product of Dyne Therapeutics Inc

The development of innovative therapies for muscle pathologies at Dyne Therapeutics, Inc. (DYN) is reflected in the 12-month net income per share chart. This indicator divides the company's total income by the total number of securities, allowing investors to assess real profit generation efficiency regardless of issuance factors, which is critical for companies in the pre-commercial growth stage.